Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
There is an urgent need for an improved vaccine against tuberculosis. Heterologous prime-boost immunization regimes induce higher levels of cellular immunity than homologous boosting with the same vaccine. Using BCG as the priming immunization in such a regime allows for the retention of the benefic...
主要な著者: | Mcshane, H, Pathan, A, Sander, C, Goonetilleke, N, Fletcher, H, Hill, A |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
2005
|
類似資料
-
Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
著者:: Whelan, K, 等
出版事項: (2009) -
Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.
著者:: Fletcher, H, 等
出版事項: (2008) -
Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
著者:: Kathryn T. Whelan, 等
出版事項: (2011-01-01) -
Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
著者:: Pathan, A, 等
出版事項: (2012) -
Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
著者:: Pathan, A, 等
出版事項: (2012)